MicroRNA‐144 relieves chronic constriction injury‐induced neuropathic pain via targeting RASA1

Zhang, Xianjie; Guo, Hongli; Xie, An; Liao, Ou; Ju, Feng; Zhou, Yukai

doi:10.1002/bab.1854

Cited by 19 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nerve injury resulted in neuropathic pain and subsequent pain hypersensitivity. Using the CCI model of neuropathic pain, Zhang et al (2020b) found that mmu-miR-144 was downregulated after inducing CCI. Proinflammatory mediators like Il-6, Il-1β and Tnfα were significantly elevated after CCI induction.…”

Section: Downregulated Micrornas In Neuropathic Pain Human Micrornas ...mentioning

confidence: 99%

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

Gada¹,

Pandey²,

Jadhav³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Neuropathic pain is a chronic pain condition seen in patients with diabetic neuropathy, cancer chemotherapy-induced neuropathy, idiopathic neuropathy as well as other diseases affecting the nervous system. Only a small percentage of people with neuropathic pain benefit from current medications. The complexity of the disease, poor identification/lack of diagnostic and prognostic markers limit current strategies for the management of neuropathic pain. Multiple genes and pathways involved in human diseases can be regulated by microRNA (miRNA) which are small non-coding RNA. Several miRNAs are found to be dysregulated in neuropathic pain. These miRNAs regulate expression of various genes associated with neuroinflammation and pain, thus, regulating neuropathic pain. Some of these key players include adenylate cyclase (Ac9), toll-like receptor 8 (Tlr8), suppressor of cytokine signaling 3 (Socs3), signal transducer and activator of transcription 3 (Stat3) and RAS p21 protein activator 1 (Rasa1). With advancements in high-throughput technology and better computational power available for research in present-day pharmacology, biomarker discovery has entered a very exciting phase. We dissect the architecture of miRNA biological networks encompassing both human and rodent microRNAs involved in the development of neuropathic pain. We delineate various microRNAs, and their targets, that may likely serve as potential biomarkers for diagnosis, prognosis, and therapeutic intervention in neuropathic pain. miRNAs mediate their effects in neuropathic pain by signal transduction through IRAK/TRAF6, TLR4/NF-κB, TXIP/NLRP3 inflammasome, MAP Kinase, TGFβ and TLR5 signaling pathways. Taken together, the elucidation of the landscape of signature miRNA regulatory networks in neuropathic pain will facilitate the discovery of novel miRNA/target biomarkers for more effective management of neuropathic pain.

show abstract

Section: Downregulated Micrornas In Neuropathic Pain Human Micrornas ...mentioning

confidence: 99%

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

Gada¹,

Pandey²,

Jadhav³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Neuropathic pain (NP) is a chronic pain, and it is a disease caused by somatosensory nervous system dysfunction or a variety of factors, including metabolic disorders, inflammation, and surgical trauma [1, 2]. At present, NP has become a major public health problem faced by all countries in the world.…”

Section: Introductionmentioning

confidence: 99%

LncRNA PCAT19 Regulates Neuropathic Pain via Regulation of miR-182-5p/JMJD1A in a Rat Model of Chronic Constriction Injury

Huo¹,

Xie²,

Bai³

et al. 2021

Neuroimmunomodulation

View full text Add to dashboard Cite

Introduction: Neuropathic pain (NP) is one of the most severe chronic pain types. In recent years, more and more studies have shown that long noncoding RNA (LncRNA) plays a key role in a variety of human diseases, including NP. However, the role of LncRNA prostate cancer-associated transcript 19 (PCAT19) in NP and its specific mechanism remain unclear. Methods: A chronic constrictive injury (CCI) rat model was established. Rat paw withdrawal threshold and paw withdrawal latency were used to evaluate the neuronal pain behavior of rats in this model. mRNA expression of PCAT19, neuroinflammatory factor, microRNA (miR)-182-5p, and Jumonji domain containing 1A (JMJD1A) were detected by quantitative real-time PCR. ELISA analysis was used to detect inflammatory factor protein expression. Dual-luciferase reporter assay was used to evaluate the targeting relationship between genes. Results: PCAT19 was continuously upregulated in CCI rats. miR-182-5p was the target of PCAT19, and miR-182-5p was increased after PCAT19 knockdown. NP behaviors such as mechanical ectopic pain and thermal hyperalgesia as well as neuroinflammation can be reduced by knocking down PCAT19. However, the injection of miR-182-5p antagomir significantly reversed the level of the NP behaviors and neuroinflammation caused by PCAT19 knockdown. Besides, dual-luciferase reporter assay showed that JMJD1A was the target gene of miR-182-5p. The level of JMJD1A in CCI rats increased with time. After PCAT19 knockdown, JMJD1A was significantly decreased, but inhibition of miR-182-5p can reverse its levels. Conclusion: This study shows that PCAT19 plays a role in NP by targeting the miR-182-5p/JMJD1A axis, and PCAT19 can be used as a new therapeutic target for NP.

show abstract

“…CCI downregulated miR‐140 and miR‐144 expression in the DRG. Intrathecally injected miR‐140 and miR‐144 agomir decreased inflammatory factor secretion and ameliorated hyperalgesia by targeting sphingosine‐1‐phosphate receptor 1 (S1PR1) and RAS P21 protein activator 1 (RASA1), respectively 43,44 …”

Section: Studying Mirna Neuropathic Pain Mechanismsmentioning

confidence: 99%

The etiological roles of miRNAs, lncRNAs, and circRNAs in neuropathic pain: A narrative review

Jiang

Wang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Non‐coding RNAs (ncRNAs) are involved in neuropathic pain development. Herein, we systematically searched for neuropathic pain‐related ncRNAs expression changes, including microRNAs (miRNAs), long non‐coding RNAs (lncRNAs), and circular non‐coding RNAs (circRNAs). Methods We searched two databases, PubMed and GeenMedical, for relevant studies. Results Peripheral nerve injury or noxious stimuli can induce extensive changes in the expression of ncRNAs. For example, higher serum miR‐132‐3p, ‐146b‐5p, and ‐384 was observed in neuropathic pain patients. Either sciatic nerve ligation, dorsal root ganglion (DRG) transaction, or ventral root transection (VRT) could upregulate miR‐21 and miR‐31 while downregulating miR‐668 and miR‐672 in the injured DRG. lncRNAs, such as early growth response 2‐antisense‐RNA (Egr2‐AS‐RNA) and Kcna2‐AS‐RNA, were upregulated in Schwann cells and inflicted DRG after nerve injury, respectively. Dysregulated circRNA homeodomain‐interacting protein kinase 3 (circHIPK3) in serum and the DRG, abnormally expressed lncRNAs X‐inactive specific transcript (XIST), nuclear enriched abundant transcript 1 (NEAT1), small nucleolar RNA host gene 1 (SNHG1), as well as ciRS‐7, zinc finger protein 609 (cirZNF609), circ_0005075, and circAnks1a in the spinal cord were suggested to participate in neuropathic pain development. Dysregulated miRNAs contribute to neuropathic pain via neuroinflammation, autophagy, abnormal ion channel expression, regulating pain‐related mediators, protein kinases, structural proteins, neurotransmission excitatory–inhibitory imbalances, or exosome miRNA‐mediated neuron–glia communication. In addition, lncRNAs and circRNAs are essential in neuropathic pain by acting as antisense RNA and miRNA sponges, epigenetically regulating pain‐related molecules expression, or modulating miRNA processing. Conclusions Numerous dysregulated ncRNAs have been suggested to participate in neuropathic pain development. However, there is much work to be done before ncRNA‐based analgesics can be clinically used for various reasons such as conservation among species, proper delivery, stability, and off‐target effects.

show abstract

MicroRNA‐144 relieves chronic constriction injury‐induced neuropathic pain via targeting RASA1

Cited by 19 publications

References 41 publications

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

LncRNA PCAT19 Regulates Neuropathic Pain via Regulation of miR-182-5p/JMJD1A in a Rat Model of Chronic Constriction Injury

The etiological roles of miRNAs, lncRNAs, and circRNAs in neuropathic pain: A narrative review

Contact Info

Product

Resources

About